ClinicalTrials.gg
Not yet recruitingNCT05731596Updated May 16, 2023

Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis

A Phase 3 interventional study of Rosuvastatin 20 Mg Oral Tablet and Coenzyme Q10 100 MG Oral Capsule in Nonalcoholic Steatohepatitis, sponsored by Tanta University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Tanta University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University — 6 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Tanta University.

Planned enrollment
10th of 12
46 · median 58
Started
2023
with 2 others
Phase 3
3 of 13
2 open now
Registered
7th of 13
by date

Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 7th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

6 of the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, or all of them as a file.
02

Study summary

This study will be a randomized, controlled, parallel study that aims to evaluate the efficacy and safety of Rosuvastatin versus Coenzyme Q10 on nonalcoholic steatohepatitis patients.

Read the detailed description
  • This study will be a randomized, controlled, parallel study.
  • It will be conducted on 46 patients diagnosed with NASH
  • The patients will be randomized into two groups:

Group 1(n=23): patients will receive Rosuvastatin 20mg/day orally

Group 2(n=23): patients will receive Coenzyme Q10 100 mg/day orally

The patients will be selected from community awareness campaigns about NASH in Alexandria , Egypt . Written informed consent will be obtained from all patients. This study will be approved by the Research Ethics Committee of Tanta University and Alexandria university.

The study duration will be 3 months.

03

Conditions studied

  • Nonalcoholic Steatohepatitis

Keywords

  • nonalcoholic steatohepatitis
  • NASH
  • NAFLD
  • Non-Alcoholic Fatty Liver Disease
  • Rosuvastatin
  • Coenzyme Q10
  • Fatty Liver
  • statin
  • Liver Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥ 18 years.
  • Gender: Both male and female patients will be included.
  • Patients have established diagnosis of NASH (based on liver ultrasonography).

Exclusion criteria

Exclusion Criteria:

  • Young ages \<18 years
  • Secondary causes of hepatic fat accumulation such as Significant alcohol consumption as defined by an average daily consumption of alcohol greater than 30 g/day in men and greater than 20 g/day in women or Long-term use of a steatogenic medication (e.g., non-Steroidal anti-inflammatory drugs (NSAIDs) amiodarone, methotrexate, tamoxifen, )
  • Patients with a known history of viral hepatitis, hemochromatosis, Wilson's disease, hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction.
  • Patients with inflammatory diseases.
  • Subjects using any other lipid-lowering agents, or any supplements known to have antioxidant activity and omega-3 supplementation for at least 3 months before participation in the trial
  • Current Pregnancy
  • Breastfeeding
  • Females On Oral pills
  • Patients with renal impairment
  • Patients with heart failure
  • Patients with cancer or with a history of cancer treatment
  • Any to coenzyme Q 10 Or statins like to anyone
  • Patients with predisposing risk factors for myopathy/rhabdomyolysis.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Active comparator
    Group 1 (Rosuvastatin group)

    Patients will receive Rosuvastatin 20mg/day orally for 3 months

    Drug: Rosuvastatin 20 Mg Oral Tablet

  • Experimental
    Group 2 (CoQ10 group)

    Patients will receive Coenzyme Q10 100 mg/day orally for 3 months

    Drug: Coenzyme Q10 100 MG Oral Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Change in liver stiffness measurement (LSM)

    LSM will be assessed by Fibro scan

    Time frame: At baseline and 12th week

  2. Change in ultrasound score

    Ultrasound score will be assessed by Ultrasonography

    Time frame: At baseline and 12th week

Secondary outcomes

  1. Demonstrate changes in Alanine aminotransferase (ALT)

    Alanine aminotransferase (ALT) in U/L

    Time frame: At baseline and 12th week

  2. Demonstrate changes in Aspartate aminotransferase (AST)

    Aspartate aminotransferase (AST) in U/L

    Time frame: At baseline and 12th week

  3. Demonstrate changes in Alkaline phosphatase (ALP)

    Alkaline phosphatase (ALP) in U/L

    Time frame: At baseline and 12th week

  4. Demonstrate changes in ɤ-glutamyltranspeptidase (GGT)

    ɤ-glutamyltranspeptidase (GGT) in U/L

    Time frame: At baseline and 12th week

  5. Demonstrate changes in Direct bilirubin

    Direct bilirubin in mg/dl

    Time frame: At baseline and 12th week

  6. Demonstrate changes in the Lipid values

    Total cholesterol(TC) in mg/dl , Triglycerides(TG) in mg/dl , LDL-Cholesterol in mg/dl , HDL-Cholesterol in mg/dl

    Time frame: At baseline and 12th week

  7. Demonstrate changes in the body weight and body mass index (BMI)

    BMI in kg/m\^2 will be calculated using the formula: BMI= \[Weight (kg)/Height (m2)\].

    Time frame: At baseline and 12th week

  8. Demonstrate changes in the Inflammatory marker : CRP

    C-reactive protein in mg/L

    Time frame: At baseline and 12th week

  9. Demonstrate changes in Serum cytokeratin 18 (Ck-18)

    Serum cytokeratin 18 (Ck-18) will be determined by Enzyme-linked Immunosorbent assay kits.

    Time frame: At baseline and 12th week

  10. Demonstrate changes in Serum transforming growth factor-beta1 (TGF-β1)

    Serum transforming growth factor-beta1 (TGF-β1) will be determined by Enzyme-linked Immunosorbent assay kits.

    Time frame: At baseline and 12th week

  11. Serum Retinol binding protein 4 (RBP-4)

    Serum Retinol binding protein 4 (RBP-4) will be determined by Enzyme-linked Immunosorbent assay kits.

    Time frame: At baseline and 12th week

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. PubMed 26707365 ↗
  • Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. PubMed 29886156 ↗
  • Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020 Oct;111S:154170. doi: 10.1016/j.metabol.2020.154170. Epub 2020 Jan 30. PubMed 32006558 ↗
  • Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015 May;61(5):1547-54. doi: 10.1002/hep.27368. Epub 2015 Mar 23. PubMed 25125077 ↗
  • Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29. No abstract available. PubMed 28714183 ↗
  • Vanni E, Marengo A, Mezzabotta L, Bugianesi E. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17. PubMed 26378641 ↗
  • Spahillari A, Mukamal KJ, DeFilippi C, Kizer JR, Gottdiener JS, Djousse L, Lyles MF, Bartz TM, Murthy VL, Shah RV. The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study. Nutr Metab Cardiovasc Dis. 2016 Nov;26(11):1039-1047. doi: 10.1016/j.numecd.2016.06.011. Epub 2016 Jun 28. PubMed 27484755 ↗
  • Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol. 2022 Jan 27;14(1):119-139. doi: 10.4254/wjh.v14.i1.119. PubMed 35126843 ↗
  • Wang W, Zhao C, Zhou J, Zhen Z, Wang Y, Shen C. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One. 2013 Oct 2;8(10):e76538. doi: 10.1371/journal.pone.0076538. eCollection 2013. PubMed 24098525 ↗
  • Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011 Mar;269(3):333-9. doi: 10.1111/j.1365-2796.2010.02305.x. Epub 2010 Nov 18. PubMed 21083855 ↗
  • Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2016 May-Jun;35(4):346-53. doi: 10.1080/07315724.2015.1021057. Epub 2015 Jul 9. PubMed 26156412 ↗
  • Chen K , Chen X , Xue H , Zhang P , Fang W , Chen X , Ling W . Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway. Food Funct. 2019 Feb 20;10(2):814-823. doi: 10.1039/c8fo01236a. PubMed 30675881 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Feb 2024, 8 months later.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Feb 16, 2023
StartEst.
Jun 2023
Primary completionEst.
Feb 2024
CompletionEst.
Apr 2024
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05731596
Lead sponsor
Tanta University
Responsible party
Hadeer Ahmed Alsayed (Principal Investigator, Tanta University) — Principal investigator
First posted
Feb 16, 2023
Start date
Jun 2023 (estimated)
Primary completion
Feb 2024 (estimated)
Completion
Apr 2024 (estimated)
Last update
May 16, 2023

Study contacts

Hadeer Ahmed Alsayed, B.Sc. Degree
Contact
hader.ahmed41996@gmail.com
00201011611651
Hadeer Ahmed Alsayed, B.Sc. Degree
principal investigator · Faculty of pharmacy , Pharos University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Coenzyme Q10

Start the discussion